

Travosant Forte[™]

The Next Generation for Canine Glaucoma

Triple Therapy in One Step



Glaucoma: An Insidious Disease

Glaucoma is a group of ocular disorders characterized by elevated intraocular pressure (IOP) that can progressively impair vision if unmanaged. Medical therapy to reduce IOP is recommended to delay onset and slow disease progression. However, many canine patients require multiple ocular hypotensive medications to achieve and maintain physiological IOP levels.

Travosant Forte™ : Triple Fixed Combination for IOP Control

Clinical evidence in glaucoma patients consistently demonstrates that **combination pressure-lowering therapies reduce IOP more than monotherapy**, with comparable or improved tolerability profiles (Boyle et al., 1998; Fechtner & Realini, 2004).

Travosant Forte™ combines three mechanisms of action into a single ophthalmic gel compounded formulation:

- **Dorzolamide** 2% – Carbonic anhydrase inhibitor (CAI) that reduces aqueous humor production
- **Betaxolol** 0.25%– Selective beta-blocker that inhibits aqueous humor synthesis
- **Travoprost** 0.004% – Prostaglandin analogue (PGA) that enhances uveoscleral outflow

This triple-combination therapy delivers robust IOP reduction, achieving 20–30% greater pressure lowering from baseline.

Demonstrated IOP Reduction

Baseline



Post Treatment



Clinical Advantages of Travosant Forte™

- Greater IOP reduction compared to monotherapy
- Improved tolerability profiles
- Enhanced eye drop adherence
- Reduced exposure to preservatives

This triple fixed-combination gel system helps minimize dilution or washout of active ingredients that can occur when multiple medications are administered in close succession.

Practical Benefits for Patients & Pet Owners

- ✓ Fewer bottles
- ✓ Fewer daily applications
- ✓ Improved convenience
- ✓ Better treatment follow-up
- ✓ Increased clinical efficiency

Prescribe for a patient today!

Online at [iFill.com](https://www.ifill.com) or call **800-754-5222**



Our Partnership with Santgar™

Stokes Healthcare is proud to partner with Santgar, a leading veterinary pharmaceutical innovator in Mexico known for its research-driven, high-quality animal health solutions. Santgar sought us out for this collaboration, recognizing our product quality, rigorous processes, and shared commitment to the same standards and values. Together, we are introducing new ophthalmic formulations to the U.S. market, expanding access to advanced veterinary therapies and improving patient outcomes.

References:

- Boyle, J. E., Ghosh, K., Gieser, D. K., & Adamsons, I. A. (1998). A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. *Ophthalmology*, 105(10), 1945–1951. [https://doi.org/10.1016/s0161-6420\(98\)91046-6](https://doi.org/10.1016/s0161-6420(98)91046-6)
- Fechtner, R. D., & Realini, T. (2004). Fixed combinations of topical glaucoma medications. *Current Opinion in Ophthalmology*, 15(2), 132–135. <https://doi.org/10.1097/00055735-200404000-00013>